Video

Dr. Arenas-Gallo highlights findings on DNA alteration frequency in Hispanic men with prostate cancer

"What we found was a very different frequency of alterations in important genes," says Camilo Arenas-Gallo, MD.

In this video, Camilo Arenas-Gallo, MD, discusses findings from the study, “Prostate Cancer Genetic Alterations in Hispanic Men,” which were presented at the 2023 American Urological Association Annual Meeting in Chicago, Illinois. Arenas-Gallo is a research fellow at Case Western Reserve University in Cleveland, Ohio.

Video Transcript:

What we did is, compiling this data that is publicly available, as I said in GENIE, [we tried] to [look at] Hispanic Whites [and] Hispanic Blacks, compared to non-Hispanic Whites and non-Hispanic Black men. Unfortunately, the database doesn't have a lot of Hispanic Blacks, so we had to remove that from our dataset. So, it's mostly self-identified Hispanic White men.

What we found was a very different frequency of alterations in important genes. For example, DNA genes that do DNA repair or genes that have been correlated with worse outcomes in men with prostate cancer. We found interesting differences between the Hispanic population with non-Hispanic Whites and Blacks, but we also found very interesting similarities. Probably the most important is that the actionable mutations that you can actually develop drugs or target therapies [from] is very similar. We didn't find any significant differences, which means that developing a targeted therapies is going to be beneficial for a high percentage of Hispanic men.

This transcription has been edited for clarity.

Related Videos
Blur image of hospital corridor | Image Credit: © whyframeshot - stock.adobe.com
Woman having telemedicine appointment with doctor | Image Credit: © Jacob Lund - stock.adobe.com
Alexander Pastuszak, MD, PhD: Is hormone therapy safe after prostate cancer radiotherapy?
Refining prostate cancer therapy strategy to address RAPTOR findings
Considering patient-reported outcomes in kidney cancer care, with Nicholas Zaorsky, MD, PhD
Soumyajit Roy, MS, MBBS: The effect of prostate cancer patient history in RAPTOR
 Nicholas Zaorsky, MD, MS: Protecting kidney function after local renal cell carcinoma therapy
Daniel Carson, MD, MS, answers a question during a Zoom video interview
Nicholas van AS, MD, MBBCH: The case for SBRT as a standard of care for localized prostate cancer
Pierre Blanchard, MD, PhD: What can hydrogel space provide to optimal prostate cancer care?
Related Content
© 2024 MJH Life Sciences

All rights reserved.